logo

For the Inventor, By the Inventor

Haarlem, Netherlands

Merck Sharp + Dohme B.v.


USPTO Granted Patents = 55

% Expired Patents = 5.5



Trademarks = 38

Forward Citations = 435

Loading Chart...
Loading Chart...

175 inventors (with patents filed for the assignee):

goldMedal Arthur A Oubrie (9 out of 9 patents)

silverMedal Tjeerd Barf (8 out of 23 patents)

bronzeMedal Christiaan Gerardus Johannes Maria Jans (8 out of 9 patents)

4.  Johannes Bernardus Maria Rewinkel (7 out of 8 patents)

5.  Adrianus Petrus Antonius De Man (6 out of 15 patents)

6.  Jacobus C H M Wijkmans (6 out of 6 patents)

7.  Wouter De Graaff (6 out of 11 patents)

8.  Maurice Petrus Wilhelmus Tak (5 out of 6 patents)

9.  Hans C A Raaijmakers (5 out of 5 patents)

10.  Cornelis Marius Timmers (5 out of 18 patents)

11.  Jan Gerard Sterrenburg (4 out of 10 patents)

12.  Martin De Kort (4 out of 9 patents)

13.  Rita Corte Real Goncalves Azevedo (4 out of 4 patents)

14.  Willem Frederik Johan Karstens (4 out of 9 patents)

15.  Wesley Peter Blackaby (4 out of 30 patents)


Core Competencies:
Combination Therapies
BTK Inhibitors
Cancer Treatment
Drug Delivery System
Antibodies
FSH Receptor Antagonists
RORgammaT Inhibitors
Vaginal Ring Applicator
Formulation
Implant Applicator
Heterocyclic Derivatives
Stable Formulations

55 patents:

1. 12156872 - Combination therapies for treating cancer (2024-12-03),
2. 11117961 - Antibodies to human programmed death receptor PD-1 (2021-09-14),
3. 11077050 - Formulation for parenteral administration (2021-08-03),
4. 11051508 - Apparatus and method for preserving mucosa (2021-07-06),
5. 11040184 - Kit for and method of assembling an applicator for inserting an implant (2021-06-22),
6. 10934296 - 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors (2021-03-02),
7. 10918515 - Vaginal ring applicator (2021-02-16),
8. 10821277 - Kit for and method of assembling an applicator for inserting an implant (2020-11-03),
9. 10556957 - Anti-CD27 antibodies (2020-02-11),
10. 10301281 - Crystal forms of a CCR5 antagonist (2019-05-28),
11. 10239883 - 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors (2019-03-26),
12. 10155259 - FSH receptor antagonists (2018-12-18),
13. 10092739 - Kit for and method of assembling an applicator for inserting an implant (2018-10-09),
14. 9925200 - Stable formulations of testosterone undecanoate (2018-03-27),
15. 9884043 - RORgammaT inhibitors (2018-02-06),
Company Overview
Merck Sharp & Dohme B.V., headquartered in Haarlem, Netherlands, is a prominent player in the field of cancer therapies. The company specializes in developing innovative treatment solutions, focusing on combination therapies and targeted therapies such as BTK inhibitors and RORgammaT inhibitors. Their research extends to advanced drug delivery systems and antibody technologies, aiming to enhance the efficacy of cancer treatment. Additionally, they explore therapeutic avenues involving FSH receptor antagonists and unique delivery methods like vaginal ring applicators.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

55 Patents

#1 in Haarlem

#150 in Netherlands

#12,903 in the World

Haarlem, NL
Haarlem, Netherlands

Merck Sharp + Dohme B.v.

Forward Citations = 435

175 inventors:

goldMedal Arthur A Oubrie (9 out of 9 patents)

silverMedal Tjeerd Barf (8 out of 23 patents)

bronzeMedal Christiaan Gerardus Johannes Maria Jans (8 out of 9 patents)

4.  Johannes Bernardus Maria Rewinkel (7 out of 8 patents)

5.  Adrianus Petrus Antonius De Man (6 out of 15 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Merck Sharp + Dohme B.v.. Retrieved from https://idiyas.com/company/merck-sharp-plus-dohme-b-v

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…